Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125


Current pharmacotherapy for the treatment of dyslipidemia associated with HIV infection.

Gebhardt A, Fichtenbaum CJ.

Expert Opin Pharmacother. 2019 Jun 28:1-11. doi: 10.1080/14656566.2019.1636033. [Epub ahead of print]


Serum Bovine Immunoglobulins Improve Inflammation and Gut Barrier Function in Persons with HIV and Enteropathy on Suppressive ART.

Utay NS, Somasunderam A, Hinkle JE, Petschow BW, Detzel CJ, Somsouk M, Fichtenbaum CJ, Weaver EM, Shaw AL, Asmuth DM.

Pathog Immun. 2019 May 3;4(1):124-146. doi: 10.20411/pai.v4i1.276. eCollection 2019.


Long-term Outcomes in a Large Randomized Trial of HIV-1 Salvage Therapy: 96-week Results of AIDS Clinical Trials Group A5241 (OPTIONS).

Gandhi RT, Tashima KT, Smeaton LM, Vu V, Ritz J, Andrade A, Eron JJ, Hogg E, Fichtenbaum CJ; ACTG A5241 study team.

J Infect Dis. 2019 May 28. pii: jiz281. doi: 10.1093/infdis/jiz281. [Epub ahead of print]


Plasma Cystatin C Associates With HIV-Associated Neurocognitive Disorder but Is a Poor Diagnostic Marker in Antiretroviral Therapy-Treated Individuals.

Kalayjian RC, Robertson KR, Albert JM, Fichtenbaum CJ, Brown TT, Taiwo BO; ACTG 5303 Study Team.

J Acquir Immune Defic Syndr. 2019 Jun 1;81(2):e49-e54. doi: 10.1097/QAI.0000000000002016.


Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE).

Grinspoon SK, Fitch KV, Overton ET, Fichtenbaum CJ, Zanni MV, Aberg JA, Malvestutto C, Lu MT, Currier JS, Sponseller CA, Waclawiw M, Alston-Smith B, Cooper-Arnold K, Klingman KL, Desvigne-Nickens P, Hoffmann U, Ribaudo HJ, Douglas PS; REPRIEVE Investigators.

Am Heart J. 2019 Jun;212:23-35. doi: 10.1016/j.ahj.2018.12.016. Epub 2019 Mar 4.


Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers.

Hoffmann U, Lu MT, Olalere D, Adami EC, Osborne MT, Ivanov A, Aluru JS, Lee S, Arifovic N, Overton ET, Fichtenbaum CJ, Aberg JA, Alston-Smith B, Klingman KL, Waclawiw M, Burdo TH, Williams KC, Zanni MV, Desvigne-Nickens P, Cooper-Arnold K, Fitch KV, Ribaudo H, Douglas PS, Grinspoon SK; REPRIEVE Investigators.

Am Heart J. 2019 Jun;212:1-12. doi: 10.1016/j.ahj.2019.02.011. Epub 2019 Mar 4.


No Significant Changes to Residual Viremia After Switch to Dolutegravir and Lamivudine in a Randomized Trial.

Li JZ, Sax PE, Marconi VC, Fajnzylber J, Berzins B, Nyaku AN, Fichtenbaum CJ, Wilkin T, Benson CA, Koletar SL, Lorenzo-Redondo R, Taiwo BO.

Open Forum Infect Dis. 2019 Feb 11;6(3):ofz056. doi: 10.1093/ofid/ofz056. eCollection 2019 Mar.


Genital HIV-1 Shedding With Dolutegravir (DTG) Plus Lamivudine (3TC) Dual Therapy.

Gianella S, Marconi VC, Berzins B, Benson CA, Sax P, Fichtenbaum CJ, Wilkin T, Vargas M, Deng Q, Oliveira MF, Moser C, Taiwo BO.

J Acquir Immune Defic Syndr. 2018 Dec 15;79(5):e112-e114. doi: 10.1097/QAI.0000000000001863. No abstract available.


Safety and Impact of Low-dose Methotrexate on Endothelial Function and Inflammation in Individuals With Treated Human Immunodeficiency Virus: AIDS Clinical Trials Group Study A5314.

Hsue PY, Ribaudo HJ, Deeks SG, Bell T, Ridker PM, Fichtenbaum C, Daar ES, Havlir D, Yeh E, Tawakol A, Lederman M, Currier JS, Stein JH.

Clin Infect Dis. 2019 May 17;68(11):1877-1886. doi: 10.1093/cid/ciy781.


Latent tuberculosis infection is associated with increased unstimulated levels of interferon-gamma in Lima, Peru.

Huaman MA, Henson D, Rondan PL, Ticona E, Miranda G, Kryscio RJ, Mugruza R, Aranda E, Ticona C, Abarca S, Heredia P, Aguirre A, Sterling TR, Garvy BA, Fichtenbaum CJ.

PLoS One. 2018 Sep 13;13(9):e0202191. doi: 10.1371/journal.pone.0202191. eCollection 2018.


Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy.

Kalayjian RC, Albert JM, Cremers S, Gupta SK, McComsey GA, Klingman KL, Fichtenbaum CJ, Brown TT, Taiwo BO; ACTG A5224s, A5303 Teams.

AIDS. 2018 Nov 13;32(17):2517-2524. doi: 10.1097/QAD.0000000000001995.


Emerging reverse transcriptase inhibitors for HIV-1 infection.

Rai MA, Pannek S, Fichtenbaum CJ.

Expert Opin Emerg Drugs. 2018 Jun;23(2):149-157. doi: 10.1080/14728214.2018.1474202. Epub 2018 May 10. Review.


Telmisartan Therapy Does Not Improve Lymph Node or Adipose Tissue Fibrosis More Than Continued Antiretroviral Therapy Alone.

Utay NS, Kitch DW, Yeh E, Fichtenbaum CJ, Lederman MM, Estes JD, Deleage C, Magyar C, Nelson SD, Klingman KL, Bastow B, Luque AE, McComsey GA, Douek DC, Currier JS, Lake JE; A5317 AIDS Clinical Trials Group Team .

J Infect Dis. 2018 May 5;217(11):1770-1781. doi: 10.1093/infdis/jiy064.


Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial.

Taiwo BO, Marconi VC, Berzins B, Moser CB, Nyaku AN, Fichtenbaum CJ, Benson CA, Wilkin T, Koletar SL, Colasanti J, Acosta EP, Li JZ, Sax PE.

Clin Infect Dis. 2018 May 17;66(11):1794-1797. doi: 10.1093/cid/cix1131.


Pre-vaccine plasma levels of soluble inflammatory indices negatively predict responses to HAV, HBV, and tetanus vaccines in HCV and HIV infection.

Shive CL, Judge CJ, Clagett B, Kalayjian RC, Osborn M, Sherman KE, Fichtenbaum C, Gandhi RT, Kang M, Popkin DL, Sieg SF, Lederman MM, Rodriguez B, Anthony DD.

Vaccine. 2018 Jan 25;36(4):453-460. doi: 10.1016/j.vaccine.2017.12.018. Epub 2017 Dec 16.


Evaluation of oral serum-derived bovine immunoglobulins in HIV-infected patients with chronic idiopathic diarrhea.

Asmuth DM, Hinkle JE, LaMarca A, Fichtenbaum CJ, Somsouk M, Utay NS, Shaw AL, Petschow BW, Detzel CJ, Weaver EM.

HIV Clin Trials. 2017 Nov-Dec;18(5-6):205-213. doi: 10.1080/15284336.2017.1401256.


Bone Health in People Living With HIV: The Role of Exercise and Directions for Future Research.

Perazzo JD, Webel AR, Fichtenbaum CJ, McComsey GA.

J Assoc Nurses AIDS Care. 2018 Mar - Apr;29(2):330-337. doi: 10.1016/j.jana.2017.09.012. Epub 2017 Oct 4. Review. No abstract available.


The Relationship Between Latent Tuberculosis Infection and Acute Myocardial Infarction.

Huaman MA, Ticona E, Miranda G, Kryscio RJ, Mugruza R, Aranda E, Rondan PL, Henson D, Ticona C, Sterling TR, Fichtenbaum CJ, Garvy BA.

Clin Infect Dis. 2018 Mar 5;66(6):886-892. doi: 10.1093/cid/cix910.


Pilot Integration of HIV Screening and Healthcare Settings with Multi- Component Social Network and Partner Testing for HIV Detection.

Rentz MF, Ruffner AH, Ancona RM, Hart KW, Kues JR, Barczak CM, Lindsell CJ, Fichtenbaum CJ, Lyons MS.

Curr HIV Res. 2017 Nov 23;15(5):372-381. doi: 10.2174/1570162X15666171017121301.


Tuberculosis and risk of acute myocardial infarction: a propensity score-matched analysis.

Huaman MA, Kryscio RJ, Fichtenbaum CJ, Henson D, Salt E, Sterling TR, Garvy BA.

Epidemiol Infect. 2017 May;145(7):1363-1367. doi: 10.1017/S0950268817000279. Epub 2017 Feb 16.


Elevated Circulating Concentrations of Interferon-Gamma in Latent Tuberculosis Infection.

Huaman MA, Deepe GS Jr, Fichtenbaum CJ.

Pathog Immun. 2016 Fall-Winter;1(2):291-303.


Differential CD4+ cell count increase and CD4+ :  CD8+ ratio normalization with maraviroc compared with tenofovir.

Chan ES, Landay AL, Brown TT, Ribaudo HJ, Mirmonsef P, Ofotokun I, Weitzmann MN, Martinson J, Klingman KL, Eron JJ, Fichtenbaum CJ, Plants J, Taiwo BO.

AIDS. 2016 Aug 24;30(13):2091-7. doi: 10.1097/QAD.0000000000001181.


Prevalence of Diagnosed and Undiagnosed Hepatitis C in a Midwestern Urban Emergency Department.

Lyons MS, Kunnathur VA, Rouster SD, Hart KW, Sperling MI, Fichtenbaum CJ, Sherman KE.

Clin Infect Dis. 2016 May 1;62(9):1066-71. doi: 10.1093/cid/ciw073. Epub 2016 Feb 21.


Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment.

Stellbrink HJ, Le Fevre E, Carr A, Saag MS, Mukwaya G, Nozza S, Valluri SR, Vourvahis M, Rinehart AR, McFadyen L, Fichtenbaum C, Clark A, Craig C, Fang AF, Heera J.

AIDS. 2016 May 15;30(8):1229-38. doi: 10.1097/QAD.0000000000001058.


HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors: A Randomized, Controlled Trial.

Tashima KT, Smeaton LM, Fichtenbaum CJ, Andrade A, Eron JJ, Gandhi RT, Johnson VA, Klingman KL, Ritz J, Hodder S, Santana JL, Wilkin T, Haubrich RH; A5241 Study Team.

Ann Intern Med. 2015 Dec 15;163(12):908-17. doi: 10.7326/M15-0949. Epub 2015 Nov 24.


Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race-ethnicity determine the degree of regimen complexity.

Tashima KT, Mollan KR, Na L, Gandhi RT, Klingman KL, Fichtenbaum CJ, Andrade A, Johnson VA, Eron JJ, Smeaton L, Haubrich RH.

HIV Clin Trials. 2015 Aug;16(4):147-56. doi: 10.1179/1945577115Y.0000000001. Epub 2015 Jul 27.


Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study.

Taiwo BO, Chan ES, Fichtenbaum CJ, Ribaudo H, Tsibris A, Klingman KL, Eron JJ, Berzins B, Robertson K, Landay A, Ofotokun I, Brown T; AIDS Clinical Trials Group A5303 Study Team.

Clin Infect Dis. 2015 Oct 1;61(7):1179-88. doi: 10.1093/cid/civ455. Epub 2015 Jun 9.


Extended-Release Niacin Versus Fenofibrate in HIV-Infected Participants With Low High-Density Lipoprotein Cholesterol: Effects on Endothelial Function, Lipoproteins, and Inflammation.

Dubé MP, Komarow L, Fichtenbaum CJ, Cadden JJ, Overton ET, Hodis HN, Currier JS, Stein JH; AIDS Clinical Trials Group A5293 Study Team.

Clin Infect Dis. 2015 Sep 1;61(5):840-9. doi: 10.1093/cid/civ385. Epub 2015 May 15.


Summaries for patients. Nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1.

Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C, Kuritzkes DR, Sagar M, Brown TT, Cohn SE, McComsey GA, Aweeka F, Fichtenbaum CJ, Presti RM, Koletar SL, Haas DW, Patterson KB, Benson CA, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JS; ACTG A5257 Team.

Ann Intern Med. 2014 Oct 7;161(7):I-22. doi: 10.7326/P14-9035. No abstract available.


Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.

Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C, Kuritzkes DR, Sagar M, Brown TT, Cohn SE, McComsey GA, Aweeka F, Fichtenbaum CJ, Presti RM, Koletar SL, Haas DW, Patterson KB, Benson CA, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JS; ACTG A5257 Team.

Ann Intern Med. 2014 Oct 7;161(7):461-71. doi: 10.7326/M14-1084. Erratum in: Ann Intern Med. 2014 Nov 4;161(9):680.


Prevalence of undiagnosed acute and chronic HIV in a lower-prevalence urban emergency department.

Moschella PC, Hart KW, Ruffner AH, Lindsell CJ, Wayne DB, Sperling MI, Trott AT, Fichtenbaum CJ, Lyons MS.

Am J Public Health. 2014 Sep;104(9):1695-9. doi: 10.2105/AJPH.2014.301953. Epub 2014 Jul 17.


Entrustment and mapping of observable practice activities for resident assessment.

Warm EJ, Mathis BR, Held JD, Pai S, Tolentino J, Ashbrook L, Lee CK, Lee D, Wood S, Fichtenbaum CJ, Schauer D, Munyon R, Mueller C.

J Gen Intern Med. 2014 Aug;29(8):1177-82. doi: 10.1007/s11606-014-2801-5. Epub 2014 Feb 21.


Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study.

Wohl DA, Arnoczy G, Fichtenbaum CJ, Campbell T, Taiwo B, Hicks C, McComsey GA, Koletar S, Sax P, Tebas P, Ha B, Massengale K, Walsh K, Stein JH.

Antivir Ther. 2014;19(2):141-7. doi: 10.3851/IMP2681. Epub 2013 Aug 28.


Randomized comparison of universal and targeted HIV screening in the emergency department.

Lyons MS, Lindsell CJ, Ruffner AH, Wayne DB, Hart KW, Sperling MI, Trott AT, Fichtenbaum CJ.

J Acquir Immune Defic Syndr. 2013 Nov 1;64(3):315-23. doi: 10.1097/QAI.0b013e3182a21611.


Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202.

McComsey GA, Daar ES, O'Riordan M, Collier AC, Kosmiski L, Santana JL, Fichtenbaum CJ, Fink H, Sax PE, Libutti DE, Gerschenson M.

J Infect Dis. 2013 Feb 15;207(4):604-11. doi: 10.1093/infdis/jis720. Epub 2012 Nov 29.


In vitro HIV infection impairs the capacity of myeloid dendritic cells to induce regulatory T cells.

Presicce P, Moreno-Fernandez ME, Rusie LK, Fichtenbaum C, Chougnet CA.

PLoS One. 2012;7(8):e42802. doi: 10.1371/journal.pone.0042802. Epub 2012 Aug 13.


Internal medicine and emergency medicine physicians lack accurate knowledge of current CDC HIV testing recommendations and infrequently offer HIV testing.

Mohajer MA, Lyons M, King E, Pratt J, Fichtenbaum CJ.

J Int Assoc Physicians AIDS Care (Chic). 2012 Mar-Apr;11(2):101-8. doi: 10.1177/1545109711430165. Epub 2012 Feb 14.


Frequency of circulating regulatory T cells increases during chronic HIV infection and is largely controlled by highly active antiretroviral therapy.

Presicce P, Orsborn K, King E, Pratt J, Fichtenbaum CJ, Chougnet CA.

PLoS One. 2011;6(12):e28118. doi: 10.1371/journal.pone.0028118. Epub 2011 Dec 5.


High-sensitivity C-reactive protein levels do not decrease with the use of statins in all persons with HIV infection.

Fichtenbaum CJ, Evans SE, Aberg JA.

AIDS. 2011 Oct 23;25(16):2053. doi: 10.1097/QAD.0b013e32834b9680. No abstract available.


Highly active antiretroviral therapy in patients infected with human immunodeficiency virus increases CD40 ligand expression and IL-12 production in cells ex vivo.

Nyakeriga AM, Ying J, Shire NJ, Fichtenbaum CJ, Chougnet CA.

Viral Immunol. 2011 Aug;24(4):281-9. doi: 10.1089/vim.2010.0142.


Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin.

Samineni D, Desai PB, Sallans L, Fichtenbaum CJ.

J Clin Pharmacol. 2012 Jun;52(6):922-31. doi: 10.1177/0091270011407494. Epub 2011 Jun 28.


Comparison of missed opportunities for earlier HIV diagnosis in 3 geographically proximate emergency departments.

Lyons MS, Lindsell CJ, Wayne DB, Ruffner AH, Hart KW, Fichtenbaum CJ, Trott AT, Sullivan PS.

Ann Emerg Med. 2011 Jul;58(1 Suppl 1):S17-22.e1. doi: 10.1016/j.annemergmed.2011.03.018.


Effect of an emergency department HIV testing program on the proportion of emergency department patients who have been tested.

Hudepohl NJ, Lindsell CJ, Hart KW, Ruffner AH, Trott AT, Fichtenbaum CJ, Lyons MS.

Ann Emerg Med. 2011 Jul;58(1 Suppl 1):S140-4. doi: 10.1016/j.annemergmed.2011.03.038.


Preliminary program evaluation of emergency department HIV prevention counseling.

Sitlinger AP, Lindsell CJ, Ruffner AH, Wayne DB, Hart KW, Trott AT, Fichtenbaum CJ, Lyons MS.

Ann Emerg Med. 2011 Jul;58(1 Suppl 1):S120-5.e1-3. doi: 10.1016/j.annemergmed.2011.03.036.


Inflammatory Markers Associated with Coronary Heart Disease in Persons with HIV Infection.

Fichtenbaum CJ.

Curr Infect Dis Rep. 2011 Feb;13(1):94-101. doi: 10.1007/s11908-010-0153-9.


Risk, reasons for refusal, and impact of counseling on consent among ED patients declining HIV screening.

Ubhayakar ND, Lindsell CJ, Raab DL, Ruffner AH, Trott AT, Fichtenbaum CJ, Lyons MS.

Am J Emerg Med. 2011 May;29(4):367-72. doi: 10.1016/j.ajem.2009.10.005. Epub 2010 Mar 25.


Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087.

Fichtenbaum CJ, Yeh TM, Evans SR, Aberg JA.

J Clin Lipidol. 2010 Jul-Aug;4(4):279-87. doi: 10.1016/j.jacl.2010.04.003.


Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults.

Jacobson JM, Lalezari JP, Thompson MA, Fichtenbaum CJ, Saag MS, Zingman BS, D'Ambrosio P, Stambler N, Rotshteyn Y, Marozsan AJ, Maddon PJ, Morris SA, Olson WC.

Antimicrob Agents Chemother. 2010 Oct;54(10):4137-42. doi: 10.1128/AAC.00086-10. Epub 2010 Jul 26.


Fenofibrate in the treatment of dyslipidemia associated with HIV infection.

Samineni D, Fichtenbaum CJ.

Expert Opin Drug Metab Toxicol. 2010 Aug;6(8):995-1004. doi: 10.1517/17425255.2010.504715. Review.


Does antiretroviral therapy increase or decrease the risk of cardiovascular disease?

Fichtenbaum CJ.

Curr HIV/AIDS Rep. 2010 May;7(2):92-8. doi: 10.1007/s11904-010-0045-5. Review.


Supplemental Content

Loading ...
Support Center